INHIBITION OF ALLOREACTIVITY INVITRO BY MONOCLONAL-ANTIBODIES DIRECTED AGAINST RESTRICTED ISOFORMS OF THE LEUKOCYTE-COMMON-ANTIGEN-(CD45)

AI LAZAROVITS*, S POPPEMA, MJ WHITE, J KARSH

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

17 Citations (Scopus)

Abstract

The leukocyte common antigen (LCA) is a protein tyrosine phosphatase and is identified by the CD45 cluster of monoclonal antibodies. CD45 is expressed in high-density on cells of hematopoietic lineage and generally is immunoprecipitated as 4 bands (220, 205, 190, and 180 KDa). Genetic studies have shown that a single gene produces additional forms of the molecule by alternate splicing including CD45RA (220, 205), CD45RO (180), and CD45RB (220, 205, 190). We have prepared a CD45RB Mab termed "MT3" that binds to a sialic acid dependent epitope. Since the LCA is one of the major targets of antilymphocyte globulin, we assessed a panel of CD45 and CD45R Mab for their ability to inhibit alloreactivity in vitro.

MT3 (CD45RB) inhibits the allogeneic MLR and inhibits CD4+ T cells from expressing interleukin 2 receptors, and prevents CD4+ CD45RA- T cells from entering the proliferative phase of the cell cycle. Mem 93 (CD45RA) inhibits the generation of cytotoxic T cells. These data suggest that the CD45RB and CD45RA isoforms of the LCA may be appropriate targets for in vivo immunotherapy.

Original languageEnglish
Pages (from-to)724-729
Number of pages6
JournalTransplantation
Volume54
Issue number4
Publication statusPublished - Oct-1992
Externally publishedYes

Keywords

  • T-CELL PROLIFERATION
  • LYMPHOCYTES-T
  • B-CELLS
  • CYTO-TOXICITY
  • RENAL-TRANSPLANTATION
  • ALLOGRAFT-REJECTION
  • SIGNAL TRANSDUCTION
  • ACTIVATION ANTIGEN
  • SURFACE MOLECULES
  • CD45 ANTIGEN

Cite this